drugset
drugset / Trial / NCT06964711

GW117 ODT （Orally Disintegrating Tablets） Safety and Pharmacokinetics Study in Healthy Subjects

NCT06964711 ↗

Phase 1 Completed 92 enrolled Beijing Greatway Pharmaceutical Technology Co.,Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of GW117 ODT in healthy volunteers

Timeline

Start
2021-07-12
Primary completion
2023-03-24
Completion
2023-03-24

Drugs

EvaluationDrugModalityDoseRoute
Subject GW117 Unknown 0.5 mg Subcutaneous
Subject GW117 Unknown 1 mg Subcutaneous
Subject GW117 Unknown 2 mg Subcutaneous
Subject GW117 Unknown 4 mg Subcutaneous

Indications

major depressive disorder